• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卵泡刺激素受体的表达水平及其在卵巢癌诊断和治疗策略中的意义。

Expression Levels of Follicle-Stimulating Hormone Receptor and Implication in Diagnostic and Therapeutic Strategy of Ovarian Cancer.

出版信息

Oncol Res Treat. 2018;41(10):651-654. doi: 10.1159/000490810. Epub 2018 Aug 27.

DOI:10.1159/000490810
PMID:30145593
Abstract

BACKGROUND

Follicle-stimulating hormone receptor (FSHR) has been shown to be expressed in ovarian cancer.

METHODS

Here we have summarized the potential therapeutic and diagnostic implication of FSHR in the ovarian cancers based on a review of the literature.

RESULTS

Current research indicates that FSHR comprises several variants: FSHR-1, FSHR-2, FSHR-3 and FSHR-4. Only FSHR-1 and FSHR-3 have biological roles. Although the level of FSHR differs in ovarian cancer tissues, few quantitative correlations have so far been reported on the expression levels of FSHR and carcinogenesis and progression of cancers.

CONCLUSION

A comprehensive understanding of the role of FSHR in the ovarian cancers may help the search for novel therapeutic and diagnostic regimens and improve the management of cancer patients.

摘要

背景

卵泡刺激素受体（FSHR）已被证实存在于卵巢癌中。

方法

我们通过文献回顾，总结了 FSHR 在卵巢癌中的潜在治疗和诊断意义。

结果

目前的研究表明，FSHR 包含几种变体：FSHR-1、FSHR-2、FSHR-3 和 FSHR-4。只有 FSHR-1 和 FSHR-3 具有生物学作用。尽管 FSHR 在卵巢癌组织中的水平不同，但迄今为止，关于 FSHR 的表达水平与癌症的发生和进展之间的定量相关性报道较少。

结论

全面了解 FSHR 在卵巢癌中的作用可能有助于寻找新的治疗和诊断方案，并改善癌症患者的管理。

相似文献

1
Expression Levels of Follicle-Stimulating Hormone Receptor and Implication in Diagnostic and Therapeutic Strategy of Ovarian Cancer.卵泡刺激素受体的表达水平及其在卵巢癌诊断和治疗策略中的意义。
Oncol Res Treat. 2018;41(10):651-654. doi: 10.1159/000490810. Epub 2018 Aug 27.
2
FSH receptor binding inhibitor restrains follicular development and possibly attenuates carcinogenesis of ovarian cancer through down-regulating expression levels of FSHR and ERβ in normal ovarian tissues.促卵泡激素受体结合抑制剂通过下调正常卵巢组织中 FSHR 和 ERβ 的表达水平来抑制卵泡发育，并可能减弱卵巢癌的癌变作用。
Gene. 2018 Aug 20;668:174-181. doi: 10.1016/j.gene.2018.05.068. Epub 2018 May 18.
3
Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells.促卵泡激素受体的过表达激活了癌前卵巢表面上皮细胞中的致癌途径。
J Clin Endocrinol Metab. 2004 Nov;89(11):5508-16. doi: 10.1210/jc.2004-0044.
4
Role of nerve growth factor and FSH receptor in epithelial ovarian cancer.神经生长因子和促卵泡激素受体在上皮性卵巢癌中的作用。
Reprod Biomed Online. 2005 Aug;11(2):194-7. doi: 10.1016/s1472-6483(10)60958-3.
5
Genetic variations altering FSH action affect circulating hormone levels as well as follicle growth in healthy peripubertal girls.改变 FSH 作用的遗传变异会影响健康青春期前女孩的循环激素水平和卵泡生长。
Hum Reprod. 2016 Apr;31(4):897-904. doi: 10.1093/humrep/dew022. Epub 2016 Feb 23.
6
Follicle-stimulating hormone induced epithelial-mesenchymal transition of epithelial ovarian cancer cells through follicle-stimulating hormone receptor PI3K/Akt-Snail signaling pathway.促卵泡激素通过促卵泡激素受体PI3K/Akt-Snail信号通路诱导上皮性卵巢癌细胞发生上皮-间质转化。
Int J Gynecol Cancer. 2014 Nov;24(9):1564-74. doi: 10.1097/IGC.0000000000000279.
7
Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.卵泡刺激素受体作为癌症重定向 T 细胞治疗的靶点。
Cancer Immunol Res. 2015 Oct;3(10):1130-7. doi: 10.1158/2326-6066.CIR-15-0047. Epub 2015 Jun 25.
8
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.大多数卵巢癌亚型表达促卵泡激素受体，且该受体是一个安全有效的免疫治疗靶点。
Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19.
9
Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.卵巢上皮性肿瘤中促卵泡激素受体的定量分析：解释副中肾系统中卵巢癌发生场效应的新方法。
Int J Cancer. 2003 Jan 20;103(3):328-34. doi: 10.1002/ijc.10848.
10
Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?促卵泡生成素受体（FSHR）：肿瘤学中的一种有前景的工具？
Mol Diagn Ther. 2016 Dec;20(6):523-530. doi: 10.1007/s40291-016-0218-z.

引用本文的文献

1
Follicle-Stimulating Hormone Receptor Expression and Its Potential Application for Theranostics in Subtypes of Ovarian Tumors: A Systematic Review.卵泡刺激素受体表达及其在卵巢肿瘤亚型诊疗中的潜在应用：一项系统综述
Cancers (Basel). 2024 Mar 13;16(6):1140. doi: 10.3390/cancers16061140.
2
FSH induces EMT in ovarian cancer via ALKBH5-regulated Snail m6A demethylation.FSH 通过 ALKBH5 调控的 Snail m6A 去甲基化诱导卵巢癌细胞 EMT。
Theranostics. 2024 Mar 3;14(5):2151-2166. doi: 10.7150/thno.94161. eCollection 2024.
3
Sex blind: bridging the gap between drug exposure and sex-related gene expression in using next-generation sequencing (NGS) data and a literature review to find the missing links in pharmaceutical and environmental toxicology studies.
性别盲点：利用下一代测序（NGS）数据弥合药物暴露与性别相关基因表达之间的差距，并通过文献综述寻找药物和环境毒理学研究中缺失的环节。
Front Toxicol. 2023 Jun 16;5:1187302. doi: 10.3389/ftox.2023.1187302. eCollection 2023.
4
Inhibitory role of a smart nano-trifattyglyceride of root in epithelial ovarian cancer, through attenuation of FSHR - c-Myc axis.根的一种智能纳米三脂肪酸甘油酯通过减弱促卵泡激素受体-c-Myc轴在上皮性卵巢癌中的抑制作用。
J Tradit Complement Med. 2021 Apr 7;11(6):481-492. doi: 10.1016/j.jtcme.2021.03.005. eCollection 2021 Nov.
5
Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.通过葡萄糖代谢转变增强卵泡刺激素受体介导的己糖激酶-2耗竭对卵巢癌的抗肿瘤作用。
J Nanobiotechnology. 2020 Nov 7;18(1):161. doi: 10.1186/s12951-020-00720-4.